Progress of apathy in Alzheimer's disease

SHUJun, WEIWenshi

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2019, Vol. 2 ›› Issue (2) : 392-397.

PDF(526 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(526 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2019, Vol. 2 ›› Issue (2) : 392-397. DOI: 10.3969/j.issn.2096-5516.2019.02.015

Progress of apathy in Alzheimer's disease

Author information +
History +

Abstract

Apathy is the most common neuropsychiatric symptom in patients with Alzheimer's disease (AD). The presence of apathy has been related to decreased quality of life, greater caregiver distress. The article mainly reviews the research progress in this neuropsychiatric syndrome, focusing on its clinical characteristic, neuroimaging studies and treatment options.

Key words

Alzheimer's disease (AD) / Apathy / Neuroimaging / Treatment

Cite this article

Download Citations
SHU Jun , WEI Wenshi. Progress of apathy in Alzheimer's disease[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2019, 2(2): 392-397 https://doi.org/10.3969/j.issn.2096-5516.2019.02.015

References

[1]
Lyketsos CG, Carrillo C, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease[J]. Alzheimer Dement, 2011, 7(5): 532-539.
[2]
Lanctot K L, Aguera-Ortiz L, Brodaty H, et al. Apathy associated with neurocognitive disorders: Recent progress and future directions[J]. Alzheimers Dement, 2017, 13(1): 84-100.
[3]
唐秋碧, 周英, 汪国成, 等. 老年痴呆患者情感淡漠与生命质量的相关性[J]. 中国老年学杂志, 2018(16): 4065-4068.
[4]
Marin RS. Differential diagnosis and classification of apathy[J]. Am J Psychiatry, 1990, 147(1): 22-30.
[5]
Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the apathy evaluation scale[J]. Psychiatry Res, 1991, 38(2): 143-162.
[6]
Levy R, Dubois B. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits[J]. Cerebral Cortex, 2006, 16(7): 916-928.
[7]
Robert P, Onyike CU, Leentjens AFG, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders[J]. Eur Psychiatry, 2009, 24(2): 98-104.
[8]
Zhao QF, Tan L, Wang HF, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: Systematic review and meta-analysis[J]. J Affect Disord, 2016, 190: 264-271.
[9]
Starkstein SE. A prospective longitudinal study of apathy in Alzheimer's disease[J]. J Neurol Neurosurg Psychiatry, 2006, 77(1): 8-11.
[10]
Ballarini T, Iaccarino L, Magnani G, et al. Neuropsychiatric subsyndromes and brain metabolic network dysfunctions in early onset Alzheimer's disease[J]. Hum Brain Mapp, 2016, 37(12): 4234-4247.
Neuropsychiatric symptoms (NPSs) often occur in early-age-of-onset Alzheimer's disease (EOAD) and cluster into sub-syndromes (SSy). The aim of this study was to investigate the association between F-FDG-PET regional and connectivity-based brain metabolic dysfunctions and neuropsychiatric SSy. NPSs were assessed in 27 EOAD using the Neuropsychiatric Inventory and further clustered into four SSy (apathetic, hyperactivity, affective, and psychotic SSy). Eighty-five percent of EOAD showed at least one NPS. Voxel-wise correlations between SSy scores and brain glucose metabolism (assessed with F-FDG positron emission tomography) were studied. Interregional correlation analysis was used to explore metabolic connectivity in the salience (aSN) and default mode networks (DMN) in a larger sample of EOAD (N = 51) and Healthy Controls (N = 57). The apathetic, hyperactivity, and affective SSy were highly prevalent (>60%) as compared to the psychotic SSy (33%). The hyperactivity SSy scores were associated with increase of glucose metabolism in frontal and limbic structures, implicated in behavioral control. A comparable positive correlation with part of the same network was found for the affective SSy scores. On the other hand, the apathetic SSy scores were negatively correlated with metabolism in the bilateral orbitofrontal and dorsolateral frontal cortex known to be involved in motivation and decision-making processes. Consistent with these SSy regional correlations with brain metabolic dysfunction, the connectivity analysis showed increases in the aSN and decreases in the DMN. Behavioral abnormalities in EOAD are associated with specific dysfunctional changes in brain metabolic activity, in particular in the aSN that seems to play a crucial role in NPSs in EOAD. Hum Brain Mapp 37:4234-4247, 2016. © 2016 Wiley Periodicals, Inc.© 2016 Wiley Periodicals, Inc.
[11]
Tunnard C, Whitehead D, Hurt C, et al. Apathy and cortical atrophy in Alzheimer's disease[J]. Int J Geriatr Psychiatry, 2011, 26(7): 741-748.
[12]
Mori T, Shimada H, Shinotoh H, et al. Apathy correlates with prefrontal amyloid deposition in Alzheimer’s disease[J]. J Neurol Neurosurg Psychiatry, 2014, 85(4): 449-455.
[13]
Clarke DE, Ko JY, Kuhl EA, et al. Are the available apathy measures reliable and valid? A review of the psychometric evidence[J]. J Psychosom Res, 2011, 70(1): 73-97.
Apathy is highly prevalent among neuropsychiatric populations and is associated with greater morbidity and worse functional outcomes. Despite this, it remains understudied and poorly understood, primarily due to lack of consensus definition and clear diagnostic criteria for apathy. Without a gold standard for defining and measuring apathy, the availability of empirically sound measures is imperative. This paper provides a psychometric review of the most commonly used apathy measures and provides recommendations for use and further research.Pertinent literature databases were searched to identify all available assessment tools for apathy in adults aged 18 and older. Evidence of the reliability and validity of the scales were examined. Alternate variations of scales (e.g., non-English versions) were also evaluated if the validating articles were written in English.Fifteen apathy scales or subscales were examined. The most psychometrically robust measures for assessing apathy across any disease population appear to be the Apathy Evaluation Scale and the apathy subscale of the Neuropsychiatric Inventory based on the criteria set in this review. For assessment in specific populations, the Dementia Apathy Interview and Rating for patients with Alzheimer's dementia, the Positive and Negative Symptom Scale for schizophrenia populations, and the Frontal System Behavior Scale for patients with frontotemporal deficits are reliable and valid measures.Clinicians and researchers have numerous apathy scales for use in broad and disease-specific neuropsychiatric populations. Our understanding of apathy would be advanced by research that helps build a consensus as to the definition and diagnosis of apathy and further refine the psychometric properties of all apathy assessment tools.Copyright © 2011 Elsevier Inc. All rights reserved.
[14]
Lueken U, Seidl U, Volker L, et al. Development of a short version of the Apathy Evaluation Scale specifically adapted for demented nursing home residents[J]. Am J Geriatr Psychiatry, 2007, 15(5): 376-385.
[15]
Cummings JL, Mega M, Gray K, et al. The Neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia[J]. Neurology, 1994, 44(12): 2308-2314.
We developed a new instrument, the Neuropsychiatric Inventory (NPI), to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions. Both the frequency and the severity of each behavior are determined. Information for the NPI is obtained from a caregiver familiar with the patient's behavior. Studies reported here demonstrate the content and concurrent validity as well as between-rater, test-retest, and internal consistency reliability; the instrument is both valid and reliable. The NPI has the advantages of evaluating a wider range of psychopathology than existing instruments, soliciting information that may distinguish among different etiologies of dementia, differentiating between severity and frequency of behavioral changes, and minimizing administration time.
[16]
Robert PH, Clairet S, Benoit M, et al. The Apathy Inventory: assessment of apathy and awareness in Alzheimer’s disease, Parkinson’s disease and mild cognitive impairment[J]. Int J Geriatr Psychiatry, 2002, 17(12): 1099-1105.
[17]
Radakovic R, Starr JM, Abrahams S, et al. A novel assessment and profiling of multidimensional apathy in Alzheimer's disease[J]. J Alzheimers Dis, 2017, 60(1): 57-67.
Apathy is a complex multidimensional syndrome frequently reported in Alzheimer's disease (AD) and is associated with impaired awareness. Here we present a psychometrically robust method to profile apathy in AD.To determine the validity and reliability of a multidimensional apathy measure, the Dimensional Apathy Scale (DAS), and explore the apathy subtype profile and its associations in AD.102 people with AD and 55 healthy controls were recruited. Participants completed the DAS, the Apathy Evaluation Scale (AES), Geriatric Depression Short form (GDS-15), and Lawton Instrumental Activities of Daily Living (LIADL). Psychometric properties of the DAS were determined. AD-Control comparison was performed to explore group differences on the DAS. Latent Class Analysis (LCA) was used to explore the profile of apathy in AD.The DAS had a good to excellent Cronbach's standardized alpha (self-rated = 0.85, informant/carer-rated = 0.93) and good convergent and divergent validity against standard apathy (AES) and depression (GDS-15) measures. Group comparison showed people with AD were significantly higher for all apathy subtypes than controls (p < 0.001), and lacking in awareness over all apathy subtype deficits. LCA showed three distinct AD subgroups, with 42.2% in the Executive-Initiation apathy, 28.4% in the Global apathy, and 29.4% in the Minimal apathy group.The DAS is a psychometrically robust method of assessing multidimensional apathy in AD. The apathy profiles in AD are heterogeneous, with additional specific impairments relating to awareness dependent on apathy subtype.
[18]
Spalletta G, Long JD, Robinson RG, et al. Longitudinal neuropsychiatric predictors of death in Alzheimer's disease[J]. J Alzheimers Dis, 2015, 48(3): 627-636.
[19]
You SC, Walsh CM, Chiodo LA, et al. Neuropsychiatric Symptoms Predict Functional Status in Alzheimer’s Disease[J]. J Alzheimers Dis, 2015, 48(3): 863-869.
[20]
Tagariello P, Girardi P, Amore M, et al. Depression and apathy in dementia: same syndrome or different constructs? A critical review[J]. Arch Gerontol Geriatr, 2009, 49(2): 246-249.
[21]
Levy ML, Cummings JL, Fairbanks LA, et al. Apathy is not depression[J]. J Neuropsychiatry Clin Neurosci, 1998, 10(3): 314-319.
[22]
Theleritis C, Politis A, Siarkos K, et al. A review of neuroimaging findings of apathy in Alzheimer's disease[J]. Int Psychogeriatr, 2014, 26(2): 195-207.
Apathy is one of the most frequent "behavioral and psychological signs and symptoms of dementia" (BPSD) encountered in Alzheimer's disease (AD). There is a growing interest in the early diagnosis of apathetic elderly patients in the community since apathy has been associated with reduced daily functioning, caregiver distress, and poor outcome. The generalization of neuroimaging techniques might be able to offer help in this domain.Within this context we conducted an extensive electronic search from the databases included in the National Library of Medicine as well as PsychInfo and Google Scholar for neuroimaging findings of apathy in AD.Neuroimaging findings lend support to the notion that frontal-subcortical networks are involved in the occurrence of apathy in AD.Longitudinal studies comparing patients and normal individuals might allow us to infer on the association between apathy and neurodegenerative diseases and what can brain imaging markers tell us about the characterization of this association, thus revealing disease patterns, helping to distinguish clinically distinct cognitive syndromes, and allowing predictions.
[23]
David R, Koulibaly M, Benoit M, et al. Striatal dopamine transporter levels correlate with apathy in neurodegenerative diseases A SPECT study with partial volume effect correction[J]. Clin Neurol Neurosurg, 2008, 110(1): 19-24.
[24]
Forstl H, Burns A, Levy R, et al. Neuropathological correlates of behavioural disturbance in confirmed Alzheimer's disease[J]. Br J Psychiatry, 1993, 163: 364-368.
[25]
Marshall GA, Fairbanks LA, Tekin S, et al. Neuropathologic correlates of apathy in Alzheimer’s disease[J]. Dement Geriatr Cogn Disord, 2006, 21(3): 144-147.
[26]
Moon Y, Moon W, Kim H, et al. Regional atrophy of the insular cortex is associated with neuropsychiatric symptoms in Alzheimer's disease patients[J]. Eur Neurol, 2014, 71(5-6): 223-229.
[27]
Donovan NJ, Wadsworth LP, Lorius N, et al. Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer disease spectrum[J]. Am J Geriatr Psychiatry, 2014, 22(11): 1168-1179.
To examine regions of cortical thinning and cerebrospinal fluid (CSF) Alzheimer disease (AD) biomarkers associated with apathy and hallucinations in a continuum of individuals including clinically normal elderly, mild cognitive impairment, and mild AD dementia.Cross-sectional and longitudinal studies.Fifty-seven research sites across North America.Eight-hundred twelve community-dwelling volunteers; 413 participants in the CSF sub-study.Structural magnetic resonance imaging data and CSF concentrations of amyloid-β 1-42, total tau, and phosphorylated tau derived from the Alzheimer Disease Neuroimaging Initiative database were analyzed. Apathy and hallucinations were measured at baseline and over 3 years using the Neuropsychiatric Inventory-Questionnaire. General linear models and mixed effects models were used to evaluate the relationships among baseline cortical thickness in seven regions, and baseline CSF biomarkers, apathy, and hallucinations at baseline and longitudinally. Covariates included diagnosis, sex, age, apolipoprotein E genotype, premorbid intelligence, memory performance, processing speed, antidepressant use, and AD duration.Reduced baseline inferior temporal cortical thickness was predictive of increasing apathy over time, and reduced supramarginal cortical thickness was predictive of increasing hallucinations over time. There was no association with cortical thickness at baseline. CSF biomarkers were not related to severity of apathy or hallucinations in cross-sectional or longitudinal analyses.These results suggest that greater baseline temporal and parietal atrophy is associated with worsening apathy and hallucinations in a large AD spectrum cohort, while adjusting for multiple disease-related variables. Localized cortical neurodegeneration may contribute to the pathophysiology of apathy and hallucinations and their adverse consequences in AD.Copyright © 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.
[28]
Hahn C, Lim HK, Won WY, et al. Apathy and white matter integrity in Alzheimer's disease: a whole brain analysis with tract-based spatial statistics[J]. PLoS One, 2013, 8(1): e53493.
[29]
Fernandez-Matarrubia M, Matias-Guiu JA, Cabrera- Martin MN, et al. Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer’s disease[J]. Int J Geriatr Psychiatry, 2018, 33(1): 141-150.
[30]
赵弘铁. Alzheimer病患者淡漠综合征的临床研究[D]. 上海: 第二军医大学, 2012.
[31]
Balthazar MLF, Pereira FRS, Lopes TM, et al. Neuropsychiatric symptoms in Alzheimer’s disease are related to functional connectivity alterations in the salience network[J]. Hum Brain Mapp, 2014, 35(4): 1237-1246.
Neuropsychiatric syndromes are highly prevalent in Alzheimer's disease (AD), but their neurobiology is not completely understood. New methods in functional magnetic resonance imaging, such as intrinsic functional connectivity or "resting-state" analysis, may help to clarify this issue. Using such approaches, alterations in the default-mode and salience networks (SNs) have been described in Alzheimer's, although their relationship with specific symptoms remains unclear. We therefore carried out resting-state functional connectivity analysis with 20 patients with mild to moderate AD, and correlated their scores on neuropsychiatric inventory syndromes (apathy, hyperactivity, affective syndrome, and psychosis) with maps of connectivity in the default mode network and SN. In addition, we compared network connectivity in these patients with that in 17 healthy elderly control subjects. All analyses were controlled for gray matter density and other potential confounds. Alzheimer's patients showed increased functional connectivity within the SN compared with controls (right anterior cingulate cortex and left medial frontal gyrus), along with reduced functional connectivity in the default-mode network (bilateral precuneus). A correlation between increased connectivity in anterior cingulate cortex and right insula areas of the SN and hyperactivity syndrome (agitation, irritability, aberrant motor behavior, euphoria, and disinhibition) was found. These findings demonstrate an association between specific network changes in AD and particular neuropsychiatric symptom types. This underlines the potential clinical significance of resting state alterations in future diagnosis and therapy.Copyright © 2013 Wiley Periodicals, Inc.
[32]
Lopez OL, Mackell JA, Sun Y, et al. Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study[J]. J Natl Med Assoc, 2008, 100(11): 1350-1358.
[33]
Waldemar G, Gauthier S, Jones R, et al. Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease[J]. Int J Geriatr Psychiatry, 2011, 26(2): 150-157.
[34]
Padala PR, Padala KP, Lensing SY, et al. Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer's disease: a double-blind, randomized, placebo-controlled trial[J]. Am J Psychiatry, 2018, 175(2): 159-168.
[35]
Bachinskaya N, Hoerr R, Ihl R, et al. Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761. Findings from a randomized controlled trial[J]. Neuropsychiatr Dis Treat, 2011, 7: 209-215.
[36]
Zhang N, Wei C, Du H, et al. The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer's disease patients[J]. Dement Geriatr Cogn Disord, 2015, 40(1-2): 85-93.
[37]
Sanchez A, Marante-Moar MP, Sarabia C, et al. Multisensory stimulation as an intervention strategy for elderly patients with severe dementia: a pilot randomized controlled trial[J]. Am J Alzheimers Dis Other Demen, 2016, 31(4): 341-350.
[38]
Ohmana H, Savikko NRN, Strandberg TE, et al. Effects of frequent and long-term exercise on neuropsychiatric symptoms in patients with Alzheimer's disease- Secondary analyses of a randomized, controlled trial (FINALEX)[J]. Eur Geriatr Med, 2017, 8 (2): 153-157.
PDF(526 KB)

Accesses

Citation

Detail

Sections
Recommended

/